Deals
Pfizer-Allergan Deal Faces In-Depth Antitrust Probe by U.S.
- Drug-makers received second request for information from FTC
- Request lengthens antitrust investigation of mega-merger
This article is for subscribers only.
U.S. antitrust officials have started an in-depth investigation into the merger of Pfizer Inc. and Allergan Plc to create a pharmaceutical giant.
The Federal Trade Commission issued a so-called second request to the companies for more information related to the review, they said in a statement Wednesday. The request, a move that was expected by the companies, lengthens the review of how the combination will affect competition.